Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma — Stella

Recruiting

Back to Locally Advanced or Metastatic Melanoma trials

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

United States

Fox Chase Cancer Center, Philadelphia, Pennsylvania

Key details

Phase

Very early testing

Sponsor

Fox Chase Cancer Center

Collaborators

Incuron

Enrollment target

~12 participants

Started

November 2022

Primary completion

March 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated April 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov